Table 1 Clinical and biochemical characteristics of the study population
|  | GSD group (n = 9) | BA group (n = 20) | P value |
|---|---|---|---|
Age at LT (years) | 9.0 (4.2–15.7) | 4.8 (0.7–17) | 0.144 |
Female sex, n (%) | 6 (67%) | 10 (50.0%) | 0.412 |
Body weight (kg) | 20.6 (12.0–57.3) | 16.8 (8.2–63.8) | 0.437 |
Body height (cm) | 113 (92–151) | 105 (76–170) | 0.571 |
PELD score | 0 (− 4 to 6.0) | − 0.5 (− 10 to 16) | 1.000 |
Preoperative laboratory variables | Â | Â | Â |
 Albumin (g/dL) | 4.2 (3.1–5.3) | 3.8 (1.9–4.5) | 0.013 |
 Total bilirubin (mg/dL) | 0.5 (0.1–1.0) | 1.9 (0.3–17.1) | 0.001 |
 Creatinine (mg/dL) | 0.5 (0.3–0.9) | 0.4 (0.1–0.6) | 0.187 |
 eGFR (ml/min/1.73 m2) | 104 (58–135) | 125 (76–234) | 0.238 |
Perioperative variables | Â | Â | Â |
 GRWR | 1.63 (1.27–2.69) | 1.9 (1.0–3.8) | 0.976 |
 Blood loss (ml) | 120 (20–1480) | 130 (35–460) | 0.698 |
 Adenoma | 4 (44%) | 0 (0%) | 0.002 |
 Post-LT AKI, n (%) | 4 (23.5%) | 13 (76.5%) | 0.422 |
Immunosuppressive regimen | Â | Â | Â |
 Cyclosporin initially, n (%) | 9 (100%) | 20 (100%) | 1.000 |
 Tacrolimus conversion, n (%) | 2 (22%) | 5 (25%) | 0.874 |
 mTOR conversion, n (%) | 3 (33%) | 0 (0%) | 0.044 |
 Rejection, n (%) | 2 (22%) | 4 (20%) | 0.893 |
 De novo HTN, n (%) | 2 (22%) | 0 (0%) | 0.032 |
Postoperative variables | Â | Â | Â |
 Total bilirubin (mg/dL) | 0.8 (0.7–1.1) | 1.1 (0.4–1.8) | 0.177 |
 Creatinine (mg/dL) | 0.7 (0.5–3.1) | 0.7 (0.5–1.0) | 0.813 |
 eGFR (ml/min/1.73 m2) | 111 (18–175) | 123 (73–174) | 0.268 |
 eGFR < 60 (ml/min/1.73m2), n (%) | 2 (22%) | 0 (0%) | 0.032 |
Albuminuria | Â | Â | Â |
 Microalbuminuria (ACR, mg/g) | 16.0 (5.6–1047) | 7.2 (2.5–68.6) | 0.099 |
 Macroalbuminuria (ACR ≥ 300 mg/g) | 2 (22%) | 0 (0%) | 0.089 |
 Follow up (years) | 15.4 (4.1–22.4) | 15.4 (4.7–24.3) | 0.637 |